HomeFilePharmacology

Pharmacology

View Category

Other

ESC 2022 | TIME STUDY

The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with...
solaci -
Learn More
Antiplatelet

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen...
solaci -
Learn More
Day 2

SOLACI-SOCIME 2022 | El Desafío de PCI en pacientes con HBR, by Dr. Aníbal Damonte

Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult...
solaci -
Learn More
Antithrombotic Anticoagulants

Are Elevated Lipoprotein (a) Levels Associated with Increased Adverse Events After Peripheral Endovascular Treatment?

Peripheral arterial disease is a manifestation of systemic atherosclerotic disease with increasing prevalence. Moreover, this disease is...
solaci -
Learn More
Antithrombotic Anticoagulants

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in...
solaci -
Learn More
Antiplatelet

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet...
solaci -
Learn More
Antiplatelet

High Risk of Bleeding after PCI: More Evidence for Short DAPT

Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy...
solaci -
Learn More
Antiplatelet

Two Safe Stents at Two Years in High Bleeding Risk

There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual...
solaci -
Learn More